Evaluation Montelukast in the Treatment of Status Asthmaticus

• Status: Unknown status
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate the effectiveness of oral montelukast (Singulair) given with other standard asthma medications and treatments in the treatment of children with status asthmaticus. Status asthmaticus is an acute asthma attack that does not respond to standard intermittent treatments but requires a continuous medication to aid in breathing. While new medications have been used to better manage chronic asthma, acute asthma exacerbations continue to be a significant cause of hospitalization and even death in children. Oral montelukast is a very safe medication that is used to manage chronic asthma in children, but it has not been studied for use in status asthmaticus. If oral montelukast, given with other standard therapies, can reduce the treatment length associated with severe, acute asthma exacerbations in children, it could potentially improve both the morbidity and burden of pediatric asthma.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Corrie Fletcher
• Treatments: Montelukast

Criteria

Inclusion criteria:

• Between ages 2-148 years

• Requiring PICU admission for status asthmaticus

• Able to take oral medication

• Pediatric asthma score > 8 on admission

Exclusion criteria:

• Intubated patients or other patients unable to take medications by mouth secondary to anatomic or pre-existing craniofacial issues

• Patients already on montelukast as their controller medication

• Patients with a known allergy to montelukast

• Any patient with phenylketonuria (PKU)

• Any patient currently on treatment with rifampin, fluconazole, or Phenobarbital medications